These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25248754)

  • 21. Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy.
    Chaowu Y; Shihua Z; Jian L; Li L; Wei F
    Circ Heart Fail; 2013 Sep; 6(5):1013-20. PubMed ID: 23873474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy.
    Windram JD; Benson LN; Dragelescu A; Yoo SJ; Mertens L; Wong D; Grosse-Wortmann L
    Congenit Heart Dis; 2015; 10(6):E258-67. PubMed ID: 26193909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia.
    Dimitrow PP; Klimeczek P; Vliegenthart R; Pasowicz M; Oudkerk M; Podolec P; Tracz W; Dubiel JS
    Int J Cardiovasc Imaging; 2008 Jan; 24(1):77-83; discussion 85-7. PubMed ID: 17624806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-intensity late gadolinium enhancement predominates in hypertrophic cardiomyopathy.
    Naeger DM; Higgins C; De Marco T; Muzzarelli S; Ordovas KG
    Clin Imaging; 2015; 39(3):432-6. PubMed ID: 25724224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed-enhancement MRI of apical hypertrophic cardiomyopathy: assessment of the intramural distribution and comparison with clinical symptoms, ventricular arrhythmias, and cine MRI.
    Amano Y; Takayama M; Fukushima Y; Kitamura M; Kumita S
    Acta Radiol; 2011 Jul; 52(6):613-8. PubMed ID: 21498307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: Current state of the art.
    Kamal MU; Riaz IB; Janardhanan R
    Cardiol J; 2016; 23(3):250-63. PubMed ID: 27064795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-enhanced myocardial T1-weighted scout (Look-Locker) imaging for the detection of myocardial damages in hypertrophic cardiomyopathy.
    Amano Y; Takayama M; Kumita S
    J Magn Reson Imaging; 2009 Oct; 30(4):778-84. PubMed ID: 19787718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early gadolinium enhancement in hypertrophic cardiomyopathy: a potential premature marker of myocardial damage.
    Pozo E; Viliani D; Aguirre N; Agudo-Quilez P; Olivera MJ; Caballero P; Jiménez-Borreguero LJ; Alfonso F
    Int J Cardiovasc Imaging; 2016 Nov; 32(11):1635-1643. PubMed ID: 27503551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death?
    Kim RJ; Judd RM
    J Am Coll Cardiol; 2003 May; 41(9):1568-72. PubMed ID: 12742299
    [No Abstract]   [Full Text] [Related]  

  • 34. Late gadolinium enhancement in cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy complicated by life-threatening ventricular tachyarrhythmia.
    Petkow-Dimitrow P; Klimeczek P; Vliegenthart R; Pasowicz M; Miszalski-Jamka T; Oudkerk M; Podolec P; Dubiel JS; Tracz W
    Kardiol Pol; 2009 Aug; 67(8A):964-9. PubMed ID: 19784900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience using gadolinium-DTPA in cardiovascular MRI.
    Nishimura T; Yamada N; Haze K; Nagata S
    Magn Reson Med; 1991 Dec; 22(2):354-7; discussion 364-5. PubMed ID: 1812370
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical evaluation of 123I-BMIPP myocardial SPECT in patients with hypertensive heart disease and hypertrophic cardiomyopathy: comparison with the findings of 201Tl SPECT and Gd enhanced magnetic resonance imaging].
    Miyanaga H; Kawasaki S; Yoneyama S; Hyougo T; Kamitani T; Takahashi T; Kunishige H
    Kaku Igaku; 1997 Feb; 34(2):85-93. PubMed ID: 9095571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical significance of abnormal high signal intensity of left ventricular myocardium by gadolinium-diethylenetriaminepenta-acetic acid enhanced magnetic resonance imaging in hypertrophic cardiomyopathy].
    Koito H; Suzuki J; Nakamori H; Ohkubo N; Wakayama Y; Iwasaka T; Inada M; Katoh T
    J Cardiol; 1995 Apr; 25(4):163-70. PubMed ID: 7752050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
    Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
    J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy.
    Teraoka K; Hirano M; Ookubo H; Sasaki K; Katsuyama H; Amino M; Abe Y; Yamashina A
    Magn Reson Imaging; 2004 Feb; 22(2):155-61. PubMed ID: 15010107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.